Owens & Minor reports Q2 adjusted EPS 36c vs. 18c last year

Reports Q2 revenue $2.7B vs. $2.56B last year. “Our Q2 performance is consistent with our expectations, as we are in the early stages of implementing our long-term strategy discussed at Investor Day in December 2023. Our previous investments in our Products & Healthcare Services segment yielded positive results and generated top-line growth in our Medical Distribution division. Our Patient Direct segment performed in line with our expectations, and we expect the segment to benefit from seasonality and recent organic investments during the back half of the year,” said Edward A. Pesicka, CEO.